trial

Pilot Study of Atomoxetine To Enhance COgnition In Patients With Schizophrenia

NCTId NCT00488163
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 20 (actual)
Sponsored by Research Foundation for Mental Hygiene, Inc.
Primary completion 2007-04
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
20 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2005-01
Primary completion
2007-04
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
atomoxetine

Sponsors

Research Foundation for Mental Hygiene, Inc.Lead Sponsor
Eli Lilly and CompanyCollaborator

Investigators

1
Joseph I. Friedman, MDPrincipal Investigator

Sites

2 total
Brentwood, United StatesNew York, United States

Facts & assertions

4 sourced
Enrollment
20
Phase
PHASE4
Primary Completion Date
2007-04
Status
COMPLETED
relationships
The graph out of here
drug
atomoxetine
drug
lead_sponsor
Research Foundation for Mental Hygiene, Inc.
company
collaborator
Eli Lilly and Company
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Joseph I. Friedman, MD
person